Background: There are no recent estimates of the incidence and mortality from cancer at a European level. Those data that are available generally refer to the mid-1990s and are of limited use for cancer control planning. We present estimates of the cancer burden in Europe in 2004, including data for the (25 Member States) European Union. Methods: The most recent sources of incidence and mortality data available in the Descriptive Epidemiology Group at IARC were applied to population projections to derive the best estimates of the burden of cancer, in terms of incidence and mortality, for Europe in 2004.
Introduction
Currently, the most recent comprehensive estimates of the incidence and mortality from cancer at a European level can be extracted from the GLOBOCAN 2002 project of IARC [1] , but there is still no way of monitoring the evolution of the burden at the European level. In 1989, the European Network of Cancer Registries (ENCR) was established within the framework of the Europe Against Cancer programme of the European Commission. One of the objectives was to provide regular information on the burden of cancer in the European Union. Starting from 1995 [2] , the ENCR published regular estimates of the incidence and prevalence of, and mortality from, cancer in the European Union using the EUCAN software [3] . The ENCR activities have, however, been interrupted, so that the latest estimates available are not sufficiently recent for today's cancer control and planning.
An attempt has been made to monitor the evolution of cancer mortality in the European Union, where it was observed that the expected number of cancer deaths in the 15 Member State European Union fell by over 9% between 1985 and 2000 [4] . During the lifetime of the Europe Against Cancer programme, favourable trends in cancer mortality were established for several common forms of cancer death in many countries [4] , which appear likely to continue in the near future [5] , although there were notable exceptions including lung cancer in women and most forms of cancer in Spain and Portugal [4] .
In the year 2000, there were 1 122 000 deaths from cancer recorded in the 25 Member States that now constitute the European Union [5] . Even if the age-specific cancer mortality rates remain constant at year 2000 levels, there will be large increases in the absolute numbers of cancer cases and deaths into the foreseeable future. Although the total population will remain fairly constant, compared with 2000, by 2015 there will be a 22% increase in the population aged >65 years and a 50% increase in the number of persons aged >80 years. Given the strong association between cancer risk and age, this will lead to a major increase in the cancer burden. Using population projections, if the age-specific death rates remain constant, the absolute numbers of cancer deaths in 2015 will increase to 1 405 000. Even if the forecast trends are taken into account, it is still expected that there will be an increase, but this will be smaller and result in an estimated figure of 1 249 000 cancer deaths [5] .
Estimates of the numbers of cancer cases and deaths in Europe for 2004 have been calculated to provide information on the cancer burden in Europe and to allow monitoring of Main category (ICD-9 'Special Coding'). the evolution of the impact of the ageing of the European population.
Materials and methods
The methods used to compute the estimates for major cancers are described in detail in GLOBOCAN 2002 [1] . In summary, we estimated incidence and mortality rates (number of cases or deaths per 100 000 per- We estimated mortality in Cyprus using incidence and survival [8] (pooled European survival from the EUROCARE-3 study), and as the simple average of the mortality rates of neighbouring countries for Bosnia and Herzegovina, and for Liechtenstein (Table 1 ). For Albania, mortality rates are known to be under-estimates of the true mortality, so the rates have been corrected (multiplied by the estimated percentage of underregistration). 
Incidence data
The methods used to estimate the sex-and age-specific incidence rates of cancer for a country fall into one of the following categories.
(i) National incidence data. 'Recent' national incidence rates are available for: Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Iceland, Finland, Ireland, Malta, Norway, Slovenia, Sweden, The Netherlands, Ukraine and the UK. National incidence rates for Belarus, Latvia, Lithuania and Slovakia have been published earlier in Cancer Incidence in Five Continents Vol. VIII [9] (Table 1) . National data are also available for Austria and Poland, but have not been used as they did not meet the data quality standards required for inclusion in Cancer Incidence in Five Continents Vol. VIII.
(ii) National mortality data. For the other countries for which national mortality is available (such as France, Germany or Italy), national incidence (I N ) can be estimated by applying a set of age-, sex-and sitespecific incidence/mortality ratios (I R /M R ), obtained from the aggregation of representative cancer registry data, to the country's national mortality (M N ): I N = M N Â I R /M R . The I R /M R ratios are obtained from a Poisson regression model of the selected registry incidence data offset by corresponding mortality data, including terms for sex and age. Fifteen models have been established, based upon the most recent incidence and mortality data from local and national European cancer registries available in the EUROCIM database [10] of the ENCR. This method is regularly used by the Descriptive Epidemiology Group of IARC, and has been shown to estimate cancer incidence accurately [2] .
(iii) Local (regional) incidence data. For Serbia and Montenegro the estimates were derived from the data of two cancer registries covering a part of the country [10] .
(iv) No data. For Bosnia and Herzegovina, and for Liechtenstein, the country-specific rates were calculated from the simple average of those of neighbouring countries (Albania, Macedonia, and Serbia and Montenegro; Austria, Belgium, France, Germany, Luxembourg and Switzerland, respectively). 
Results
In 2004 in Europe, there were an estimated 2 886 800 incident cases of cancer diagnosed (Table 2 ) and 1 711 000 cancer deaths ( Table 3 ). The most common incident form of cancer in Europe in 2004 was lung cancer (381 500 cases, 13.2% of all incident cases), followed by colorectal cancer (376 400, 13%) and breast cancer (370 100, 12.8%) (Figure 1 ). Lung cancer was also the largest cause of cancer death (341 800 deaths, 20% of all deaths), followed by colorectal (203 700, 11.9%), stomach (137 900, 8.1%) and breast (129 900, 7.6%) (Figure 2 ).
In men, there were an estimated 1 534 700 incident cases of cancer of all forms (except non-melanoma skin cancer) diagnosed. There were 298 600 new cases of lung cancer (19.4%), and prostate cancer was the second most frequent incident form of cancer in men with 237 800 new cases estimated (15.5%). There were 197 200 new cases of colorectal cancer (12.8%) and, despite its falling incidence and mortality, there were 102 800 new cases of stomach cancer (6.7%) (Table 4A) . Mortality reflects the cancer prognosis, and in men there were 962 600 cancer deaths recorded (Table 5A) , of which over one-quarter (268 300) were lung cancer, by far the most common cause of death. Colorectal cancer was the second major cancer killer in men with an estimated 103 300 deaths from this cause (10.7%). This was followed by prostate cancer, with 85 200 deaths estimated (8.9%).
In women, breast cancer was by far the most common incident form of cancer, with an estimated 370 100 new cases diagnosed (27.4% of all incident cases in women). Colorectal cancer was the second most common incident form of cancer in women (179 200, 13.25%), followed by cancer of the uterus, cervix and corpus combined, of which 133 800 cases were recorded (9.9%). There were an estimated 82 900 new cases of lung cancer diagnosed in women in Europe (Table 4B) .
Breast cancer was also the most common form of cancer death in women in Europe, with 129 900 deaths (17.4%). There were 100 400 deaths from colorectal cancer (13.4%) and 73 500 deaths from lung cancer (9.8%) ( Table 5B) .
European Union
In the European Union, there were over two million (2 060 400) incident cases of cancer in 2004 and over one million cancer deaths (1 161 300).
Prostate cancer was the most common form of cancer in men (202 100 incident cases, 18.1% of all incident cases), closely followed by lung cancer (196 100, 17.6%). Colorectal cancer ranked third (149 400 cases, 13.4%), followed by bladder cancer, the fourth most common, with 91 000 (8.2%) new cases. However, due to differences in coding practices between European countries, the rubric 'bladder cancer' includes non-invasive tumours. Stomach cancer (53 800 cases) was slightly more common than oral cavity cancer (52 500) (Table 4A ). In women, with an 8% lifetime risk, breast cancer was the most common incident form of cancer (275 100 cases, 29% of all incident cases), while colorectal cancer was second (129 800, 13.7%). There were 81 500 (8.6%) cases of uterus cancer and 62 000 (6.5%) incident cases of lung cancer (Table 4B) .
Lung cancer continued to be the most common cause of cancer death in men in the European Union, with 178 400 deaths estimated in 2004 (27.3% of all cancer deaths), and the lifetime risk of dying of 5.5%. Colorectal cancer ranked second (72 300 deaths, 11.1%), followed by prostate cancer (68 200, 10.4%). In women, breast cancer is the leading cause of death in the European Union (88 400 deaths, 17.4% of total). Colorectal cancer was the second most common cause of cancer death (67 000, 13.2%), with lung cancer clearly established as the third most frequent cause of cancer deaths in women (55 900 deaths, 11%) (Table 5B) .
Discussion
With 2 886 800 incident cases and 1 711 000 deaths in 2004, cancer remains an important public health problem in Europe, and the ageing of the European population will cause these numbers to continue to increase even if age-specific rates remain constant [5] . Lung, colorectal and breast cancer represent the three most common incident forms of cancer, accounting for two-fifths of the total European cancer burden (Table 2) . Lung, colorectum, stomach and breast cancers account for nearly half of all cancer deaths in Europe (Table 3) .
The estimates provided herein give a good indication of the burden of cancer incidence and death throughout Europe, and help clarify the priorities for cancer control action. The overwhelming majority of lung cancer is caused by tobacco smoking [11, 12] and tobacco control is clearly a number one priority in Europe, aimed not only at men, but increasingly targeted towards women.
Although there have been recent declines in breast cancer mortality rates in some European Union countries [4] , breast cancer remains of key importance to public health in Europe. Prospects for primary prevention are unclear at present and tamoxifen no longer appears to be a candidate for chemoprevention in the general population of women [13] . Population screening with mammography is effective at reducing mortality when quality control procedures are in place [14] and there are slow but continual increases taking place in treatment outcome [15] , reflected by the very high ratio of the lifetime risk of getting the disease (7.8%) to that of dying from the disease (2%) observed in the European Union. However, there is still a clear need to accelerate prospects for preventing women getting breast cancer as well as dying from the disease.
Colorectal cancer is the third most common form of cancer in men and the second most common form of cancer in women in Europe, but it ranked second in frequency of deaths in both men and women. The potential to avoid many deaths from colorectal cancer has been available for several years [16, 17] , although progress in implementing what is known has been remarkably slow.
What is very clear is that if we wish to make great progress quickly against cancer in Europe, then the need is evident to make a concerted attack on the big killers: lung, colorectal, breast and stomach cancer.
Thankfully, stomach cancer incidence and mortality are declining throughout Europe, in both men and women [4] . Lung cancer incidence and mortality will be reduced by effective tobacco control, and while there has been substantial progress in men in Europe, the situation in women, particularly young women, is cause for concern. Furthermore, the situation differs greatly between Northern Europe and Central and Eastern Europe (Figure 3 ) and the latter region should be a special target for tobacco control.
The introduction of organised mammographic screening programmes throughout Europe will lead to a reduction in breast cancer mortality. The maximum effect will be derived from programmes with effective quality control procedures in place. Similarly, screening for colorectal cancer has been shown to be effective [18] and there is a need for organised colorectal cancer screening programmes throughout Europe.
These are among the key recommendations of the recently revised European Code Against Cancer, which provides a public health roadmap for cancer risk reduction in Europe [18] .
